Skip to main content

Table 3 HIV treatment and markers of immunity

From: HIV-associated neurocognitive disorders at Moi teaching and referral hospital, Eldoret, Kenya

Variable

N

Median (IQR) or n (%)

Duration since diagnosis of HIV (Months)

360

107.0 (71.5, 132.0)

 Range (Min. – Max.)

 

1.0–181.0

Duration before ART initiation (Months)

360

44.0 (4.5, 78.5)

 Range (Min. – Max.)

 

0.0–166.0

Duration of ART use (Months)

360

88.0 (51.0, 122.5)

 Range (Min. – Max.)

 

1.0–141.0

Duration of current ART (Months)

360

51.0 (17.0, 76.0)

 Range (Min. – Max.)

 

0.0–147.0

ART Line

 First line (NRTI + NNRTI)

360

286 (79.4%)

 Second line (NRTI + PI)

 

74 (20.6%)

Others

 Dapsone

 

5 (1.4%)

 Septrin

359

353 (98.3%)

 Septrin/Isoniazid

 

1 (0.3%)

Suppressed viral load (< 1000 copies/ml)

358

303 (84.6%)

Baseline CD4 cell count per mm3

304

243.0 (10.8.0, 399.0)

 Range (Min. – Max.)

 

1.0–1459.0

 < 200.0

 

122 (40.1%)

 200.0–499.0

304

132 (43.4%)

 ≥ 500.0

 

50 (16.4%)

Current CD4 cell count per mm3

360

491.0 (336.5, 701.0)

 Range (Min. – Max.)

 

1.0–1845.0

 < 200.0

 

33 (9.2%)

 200.0–499.0

360

153 (42.5%)

 ≥ 500.0

 

174 (48.3%)

WHO Clinical stage

 Stage 1

 

122 (35.6%)

 Stage 2

343

61 (17.8%)

 Stage 3

 

132 (38.5%)

 Stage 4

 

28 (8.2%)

  1. IQR Inter Quartile Range
  2. N is less than 360 in other variables due to missing data